natgillin/translations-raw huggingface dataset:
Pakningsstørrelser og yderligere oplysninger <Lægemidler, der indeholder tranexamsyre> indeholder: [Udfyldes nationalt]
What <Tranexamic acid - containing medicinal products> <Tranexamic acid - containing medicinal products> is and what it is used for
• tidligere har haft kramper.
• have a history of convulsions.
Undtaget er tilfælde, hvor De har akut alvorlig blødning og blodprøver har vist, at den mekanisme, der nedsætter blodets evne til at størkne (fibrinolyse), er aktiveret.
• If you have excessive clotting or bleeding throughout your body (disseminated intravascular coagulation), <Tranexamic acid - containing medicinal products> may not be right for you, except if you have acute severe bleeding and blood test have shown the process that inhibits blood clotting called fibrinolysis is activated.
Opbevaring [Udfyldes nationalt]
[To be completed nationally]
112 tabletter
112 tablets
200 mg Tablet, filmovertrukket
200 mg Film-coated tablet
Brug ikke kemiske desinfektionsmidler.
Do not use chemical disinfectants.
DATO FOR FØRSTE TILLADELSE/FORNYELSE AF TILLADELSEN Dato for første markedsføringstilladelse: 03/07/2015
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 03/07/2015
Bovint serum Basalmedium Dimethylsulfoxid
Bovine serum Basal medium Dimethyl sulfoxide
MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE) EU/2/15/182/001
MARKETING AUTHORISATION NUMBER(S) EU/2/15/182/001
Det er vigtigt, at suspensionen, efter at være blevet optøet, straks blandes i solvensen for at beskytte cellerne.
It is important that the suspension, after being thawed, is mixed immediately into the solvent to protect the cells.
Desinficér vaccinationsudstyret ved at koge det i vand i 20 minutter eller ved autoklavering (15 minutter ved 121 °C).
Disinfect vaccinating equipment by boiling in water for 20 minutes or by autoclaving (15 minutes at 121 °C).
MÆNGDEN AF AKTIVT STOF (AKTIVE STOFFER) HVT/ILT-138
QUANTITY OF THE ACTIVE SUBSTANCE(S) HVT/ILT-138
TEKSTEN ”TIL DYR” For animal treatment only.
THE WORDS “FOR ANIMAL TREATMENT ONLY” For animal treatment only.
Enhver, som har til hensigt at fremstille, indføre, besidde, sælge, levere og/eller anvende Innovax-ILT, skal rådføre sig med det relevante medlemslands kompetente myndighed vedrørende gældende vaccinationspolitik forinden fremstilling, indførsel, besiddelse, salg, levering og/eller anvendelse finder sted.
Any person intending to manufacture, import, possess, sell, supply and/or use Innovax-ILT must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.
Vaccinen administreres ved subkutan injektion i nakken.
The vaccine is administered by subcutaneous injection in the neck.
Yderligere information om dette lægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu.
Detailed information on this product is available on the website of the European Medicines Agency: (http://www.ema.europa.eu/).
Må ikke blandes med andre lægemidler til dyr, undtagen Nobilis Rismavac og den solvens, der leveres til brug sammen med dette veterinærlægemiddel.
Do not mix with any other veterinary medicinal product except Nobilis Rismavac and the solvent supplied for use with the veterinary medicinal product.
Immunitetens varighed: ILT: 60 uger, MD: hele risikoperioden.
Duration of immunity: ILT: 60 weeks, MD: entire risk period.
Ved subkutan vaccination bør der drages omsorg for at undgå beskadigelse af blodkarrene på halsen af kyllingerne.
During subcutaneous vaccination, care should be taken to prevent damage of the blood vessels in the neck of the chickens.
Fremstilling, indførsel, besiddelse, salg, levering og/eller anvendelse af Innovax-ILT kan være forbudt i et medlemsland på hele eller en del af medlemslandets område i henhold til national lovgivning.
The manufacture, import, possession, sale, supply and/or use of Innovax-ILT may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
ADVARSEL: Det er i nogle tilfælde set, at ampuller er eksploderet ved pludselige temperaturændringer.
CAUTION: Ampoules have been known to explode on sudden temperature changes.
Der er ikke observeret nogen symptomer efter administration af 10 gange normal vaccinedosis.
No symptoms were observed after the administration of a 10-fold dose of vaccine.
Overdosis (symptomer, nødforanstaltninger, modgift): Der er ikke observeret nogen symptomer efter administration af 10 gange normal vaccinedosis.
Overdose (symptoms, emergency procedures, antidotes): No symptoms were observed after the administration of a 10-fold dose of vaccine.
Der foreligger data vedrørende sikkerhed og virkning, som viser, at denne vaccine kan gives samme dag som, men ikke blandet med Nobilis ND Clone 30 eller Nobilis ND C2.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed with, Nobilis ND Clone 30 or Nobilis ND C2.
Suspension: - Type I-glasampuller, der indeholder 2.000 eller 4.000 doser.
Suspension: - Type I glass ampoules containing 2,000 or 4,000 doses.
INDGIVELSESVEJ(E) Læs indlægssedlen inden brug.
ROUTE(S) OF ADMINISTRATION Read package leaflet before use.
BILAG II A. FREMSTILLER AF DE BIOLOGISK AKTIVE STOFFER OG FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE B. BETINGELSER ELLER BEGRÆNSNINGER FOR MARKEDSFØRINGSTILLADELSEN VEDRØRENDE UDLEVERING OG BRUG C. ANGIVELSE AF MRL-VÆRDIER D. ANDRE FORHOLD OG BETINGELSER FOR MARKEDSFØRINGSTILLADELSEN
ANNEX II A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND> MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Når dette produkt blandes med Nobilis Rismavac, bør begge fortyndes i samme pose med solvens på samme måde (400 ml solvens for hver 2.000 doser af begge produkter eller 800 ml solvens for hver 4.000 doser af begge produkter).
When this product is mixed with Nobilis Rismavac, both should be diluted in the same solvent bag in the same way (400 ml of solvent for each 2,000 doses of both products or 800 ml of solvent for each 4,000 doses of both products).
Når Innovax-ILT blandes med Nobilis Rismavac, kan udviklingen af immunitet mod ILT være forsinket hos dyr med maternelt overførte antistoffer.
When Innovax-ILT is mixed with Nobilis Rismavac the development of immunity towards ILT may be delayed in animals with maternally derived antibodies.
Efter at have tilsat indholdet af ampullen til solvensen, er det klargjorte produkt en klar, rødfarvet suspension til injektion.
After adding the content of the ampoule to the solvent, the ready to use product is a clear, red coloured suspension for injection.
Der bør træffes passende foranstaltninger for at undgå at udsætte hænder, øjne og tøj for kontakt med suspensionen.
Care should be exercised to prevent contaminating your hands, eyes and clothing with the suspension.
1 PFU: plaquedannende enheder.
1 PFU: plaque forming units.
Da det er en levende vaccine, udskilles vaccinestammen fra vaccinerede fugle og kan spredes til kalkuner.
As a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys.
Anvend solvens (Solvens til celleassocierede hønsevacciner) til rekonstitution.
Use solvent (Solvent for cell associated poultry vaccines) for reconstitution.
Fertilitet: Der foreligger ingen oplysninger vedrørende anvendelse til kommende ynglende fugle.
Fertility: No information is available on use in future breeding birds.
Særlige advarsler for hver dyreart: Vaccinér kun raske daggamle kyllinger.
Special warnings for each target species: Vaccinate healthy one-day-old chicks only.
Ampullerne må derfor ikke optøs i varmt eller iskoldt vand.
Do not thaw in hot or ice cold water.
VETERINÆRLÆGEMIDLETS NAVN Innovax-ILT
NAME OF THE VETERINARY MEDICINAL PRODUCT Innovax-ILT
Der foreligger ingen oplysninger vedrørende anvendelse til kommende ynglende fugle.
No information is available on use in future breeding birds.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING En dosis (0,2 ml) rekonstitueret vaccine indeholder:
QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (0.2 ml) of reconstituted vaccine contains:
Træk en portion solvens op i sprøjten for at skylle ampullen.
Withdraw a portion of the solvent into the syringe to rinse the ampoule.
DOSERING FOR HVER DYREART, ANVENDELSESMÅDE OG INDGIVELSESVEJ Efter fortynding administreres 1 dosis på 0,2 ml vaccine pr. kylling ved subkutan injektion i nakken.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION After dilution, administer 1 dose of 0.2 ml of vaccine per chicken by subcutaneous injection in the neck.
Posen med vaccine bør forsigtigt roteres gentagne gange under vaccinationen for at sikre vaccinesuspensionen forbliver homogen og at den korrekte vaccinevirus titer indgives (f.eks. ved vaccinationer af længere varighed).
The bag of vaccine should be gently swirled frequently during vaccination to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titre is administered (e.g. during long vaccination sessions).
Der foreligger oplysninger om sikkerhed og virkning, som viser, at Innovax-ILT kan blandes i samme solvens og gives sammen med Nobilis Rismavac i medlemslande, hvor denne vaccine er godkendt.
Safety and efficacy data are available which demonstrate that Innovax-ILT can be mixed in the same solvent and administered with Nobilis Rismavac in Member States where this vaccine is authorized.
PFU: plaquedannende enheder.
PFU: plaque forming units.
Dosering: En enkelt injektion på 0,2 ml pr. kylling, som er en dag gammel, subkutant.
Posology: One single injection of 0.2 ml per chick at the age of one day, by the subcutaneous route.
VETERINÆRLÆGEMIDLETS NAVN Solvens til celleassocierede hønsevacciner
NAME OF THE VETERINARY MEDICINAL PRODUCT Solvent for cell associated poultry vaccines
Såfremt denne blanding anvendes, er det for MD påvist, at immunitet indtræder efter 5 dage.
For this mixed use, an onset of immunity of 5 days has been demonstrated for MD.
Innovax-ILT er en virussuspension, som leveres i glasampuller, der opbevares i flydende kvælstof.
Innovax-ILT is a virus suspension packed in glass ampoules and stored in liquid nitrogen.
Anvend 400 ml solvens for hver 2.000 doser cellesuspension eller 800 ml solvens for hver 4.000 doser cellesuspension.
Use 400 ml of solvent for each 2,000 doses of cell suspension or 800 ml of solvent for each 4,000 doses of cell suspension.
Opbevaringstid efter rekonstituering ifølge anvisning: 2 timer ved en temperatur under 25 °C.
Shelf life after reconstitution according to directions: 2 hours at a temperature below 25 °C.
Stik kanylen gennem proppen på posen med solvens, og tilsæt langsomt og forsigtigt indholdet af sprøjten til solvensen.
Insert the needle through the stopper of the solvent bag and add slowly and gently the contents of the syringe to the solvent.
Immunitetens indtræden: ILT: 4 uger, MD: 9 dage.
ILT: 4 weeks, MD: 9 days.
5 poser med 400 ml solvens eller 5 poser med 800 ml solvens.
5 bags of 400 ml solvent or 5 bags of 800 ml solvent.
Kyllinger
Chickens.
Opbevares og transporteres nedfrosset i flydende kvælstof (-196 °C).
Store and transport frozen in liquid nitrogen (-196 °C).
Cellesuspension: Opbevares og transporteres nedfrosset i flydende kvælstof (-196 °C).
Cell suspension: Store and transport frozen in liquid nitrogen (-196 °C).
De skal optøs i rent vand ved 25-27 °C.
For this reason, thaw the ampoules in clean water at 25-27 °C.
I tilfælde af uheld er det vigtigt at forebygge risikoen for alvorlige sår på grund af flydende kvælstof eller ampullerne; når en ampul tages op af beholderen, skal den derfor holdes i håndfladen iført handske væk fra krop og ansigt.
In case of an accident to prevent serious wounds by either the liquid nitrogen or the ampoules when removing an ampoule from the canister, hold palm of gloved hand away from body and face.
Vaccinen stimulerer aktiv immunitet mod infektiøs laryngotracheitis og Marek's disease hos kyllinger.
The vaccine induces active immunity against infectious laryngotracheitis and Marek's disease in chickens.
antal ampuller optøs hurtigt ved nedsænkning i rent vand ved 25-27 °C.
The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25-27 °C.
Fastgjort på staven er en farvet klemme som viser antal doser (2.000 doser: lakse-pink farvet klemme og 4.000 doser: Gul farvet klemme).
Five ampoules per cane, attached to the cane is a coloured clip displaying the dose (2,000 doses: salmon-pink coloured clip, and 4,000 doses: yellow coloured clip).
VETERINÆRLÆGEMIDLETS NAVN Innovax-ILT, suspension og solvens til injektionsvæske, suspension, til kyllinger
NAME OF THE VETERINARY MEDICINAL PRODUCT Innovax-ILT, suspension and solvent for suspension for injection for chickens
INDLÆGSSEDDEL: Innovax-ILT, suspension og solvens til injektionsvæske, suspension, til kyllinger
PACKAGE LEAFLET: Innovax-ILT suspension and solvent for suspension for injection for chickens
Opbevaringstid for cellesuspension i salgspakning: 3 år.
Shelf life of the cell suspension as packaged for sale: 3 years.
Træk forsigtigt indholdet af ampullen op i en steril sprøjte, påsat en 18-G kanyle.
Gently withdraw the contents of the ampoule into a sterile syringe, mounted with an 18 gauge needle.
OPBEVARINGSBETINGELSER Opbevares ved temperaturer under 25 °C.
STORAGE CONDITIONS Store below 25 °C.
Cellesuspension:
Cell suspension:
B. BETINGELSER ELLER BEGRÆNSNINGER FOR MARKEDSFØRINGSTILLADELSEN VEDRØRENDE UDLEVERING OG BRUG
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Suspension og solvens til injektionsvæske, suspension.
PHARMACEUTICAL FORM Suspension and solvent for suspension for injection.
Vaccinen er en celleassocieret levende, rekombinant kalkunherpesvirus (HVT), der udviser gD- og gIglycoproteiner over for infektiøs laryngotracheitis-virus.
The vaccine is a cell-associated live recombinant turkey herpesvirus (HVT) expressing the gD and gI glycoproteins of infectious laryngotracheitis virus.
4.2 Terapeutiske indikationer med angivelse af dyrearter, som lægemidlet er beregnet til Til aktiv immunisering af daggamle kyllinger for at reducere mortalitet, kliniske symptomer og læsioner forårsaget af infektion med aviær infektiøs laryngotracheitis-virus (ILTV) og Marek's disease-virus (MDV).
4.2 Indications for use, specifying the target species For active immunisation of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus.
Fjern skyllevæsken fra ampullen med sprøjten og injicér den forsigtigt i posen med solvens.
Remove the washing from the ampoule and inject it gently into the solvent bag.
Til aktiv immunisering af daggamle kyllinger for at reducere dødelighed, kliniske symptomer og læsioner forårsaget af infektion med aviær infektiøs laryngotracheitis-virus (ILTV) og Marek's disease-virus (MDV (smitsom hønselammelse)).
For active immunization of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus.
Farmakoterapeutisk gruppe: Immunologica til hønsefugle, levende virale vacciner ATCvet-kode: QI01AD.
Pharmacotherapeutic group: immunologicals for Aves, live viral vaccines for domestic fowls.
Beholder: Opbevar beholderen med flydende kvælstof sikkert, idet den placeres opretstående i et rent, tørt rum med god ventilation, som er adskilt fra ruge-/kyllingekasser i rugeriet.
Container: Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery.
Opbevar beholderen med flydende kvælstof sikkert, idet den placeres opretstående i et rent, tørt rum med god ventilation, som er adskilt fra ruge-/kyllingekasser i rugeriet.
Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery.
Inden ampuller tages op af beholderen med flydende kvælstof skal man iklæde sig beskyttelsesudstyr bestående af handsker, lange ærmer, en ansigtsmaske og beskyttelsesbriller.
Before withdrawing ampoules from the liquid nitrogen canister, protective equipment consisting of gloves, long sleeves and a facemask and goggles should be worn.
- 800 ml solvens i pose af polyethylen eller flerlagspose af plast.
- 800 ml polyethylene or multilayer plastic bags of solvent.
- 400 ml solvens i pose af polyethylen eller flerlagspose af plast.
- 400 ml polyethylene or multilayer plastic bags of solvent.
Inden ampuller tages op af beholderen med flydende kvælstof skal man iklæde sig beskyttelsesudstyr bestående af handsker, lange ærmer, ansigtsmaske og beskyttelsesbriller.
Before withdrawing ampoules from the liquid nitrogen canister, use a personal protective equipment consisting of gloves, long sleeves and facemask and goggles.
Celleassocieret levende, rekombinant kalkunherpesvirus (stamme HTV/ILT-138) , der udviser glycoproteinerne gD og gI over for infektiøs laryngotracheitis-virus: 103.1 - 104.1 PFU1.
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus:
DYREARTER Kyllinger
TARGET SPECIES
Behandling med Neoclarityn reducerede også signifikant påvirkningen af søvn og daglig funktionsevne, målt ved en fire-points skala, der anvendtes for at vurdere disse parametre.
Treatment with Neoclarityn also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.
Sikkerheden af desloratadin syrup-formuleringen, som indeholder samme koncentration af desloratadin som Neoclarityn oral opløsning, blev imidlertid påvist i tre pædiatriske studier.
However, the safety of desloratadine syrup formulation, which contains the same concentration of desloratadine as Neoclarityn oral solution, was demonstrated in three paediatric trials.
Hvornår Neoclarityn skal bruges
When Neoclarityn should be used
Hvad Neoclarityn er Neoclarityn indeholder desloratadin, som er et antihistamin.
What Neoclarityn is Neoclarityn contains desloratadine which is an antihistamine.
Vand har ingen indflydelse på biotilgængeligheden for Neoclarityn smeltetabletter.
Water had no effect on the bioavailability of Neoclarityn orodispersible tablets.
Da Neoclarityn oral opløsning indeholder samme koncentration af desloratadin, var et bioækvivalensstudie ikke nødvendigt, og den orale opløsning forventes at være ækvivalent med syruppen og tabletten.
As Neoclarityn oral solution contains the same concentration of desloratadine, no bioequivalence study was required and it is expected to be equivalent to the syrup and tablet.
Virkningen af Neoclarityn smeltetablet forventes derfor at være den samme som med Neoclarityn tabletformuleringen.
Therefore, the efficacy of Neoclarityn orodispersible tablet is expected to be the same as with the Neoclarityn tablet formulation.
Neoclarityn regulerede effektivt symptomerne i 24 timer.
Neoclarityn effectively controlled symptoms for 24 hours.
Neoclarityn-tabletter regulerede effektivt symptomerne i 24 timer.
Neoclarityn tablets effectively controlled symptoms for 24 hours.
I to placebokontrollerede seks-ugers studier hos patienter med kronisk idiopatisk urticaria var Neoclarityn effektivt til at lindre kløe og mindske størrelsen og antallet af kløende udslæt ved slutningen af det første doseringsinterval.
In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Neoclarityn was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval.
Hvorvidt amningen skal fortsættes eller om behandlingen med Neoclarityn skal seponeres/undlades skal vurderes ud fra afvejning af barnets fordele ved amning og kvindens fordele ved behandling.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Neoclarityn therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Under markedsføring af Neoclarityn er tilfælde af alvorlige allergiske reaktioner (vejrtrækningsbesvær, hiven efter vejret, kløe, kløende udslæt og hævelse) blevet rapporteret meget sjældent.
During the marketing of Neoclarityn, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely.
Du skal udvise forsigtighed, hvis du tager Neoclarityn sammen med alkohol
Use caution when taking Neoclarityn with alcohol.
Yderligere oplysninger om Neoclarityn findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu.
Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.
For en sikkerheds skyld bør Neoclarityn undgås under graviditet.
As a precautionary measure, it is preferable to avoid the use of Neoclarityn during pregnancy.
Neoclarityn-tabletter indeholder lactose.
Neoclarityn tablets contain lactose.
Hvis du har glemt at tage Neoclarityn
If you forget to take Neoclarityn
Neoclarityn smeltetabletter indeholder aspartam Dette præparat indeholder aspartam.
Neoclarityn orodispersible tablet contains aspartame This product contains aspartame.
Klinisk virkning og sikkerhed I et flerdosisstudie var Neoclarityn smeltetabletter veltolereret.
Clinical efficacy and safety In a multiple dose trial, Neoclarityn orodispersible tablets were well tolerated.
1 filmovertrukket tablet 2 filmovertrukne tabletter 3 filmovertrukne tabletter 5 filmovertrukne tabletter 7 filmovertrukne tabletter 10 filmovertrukne tabletter 14 filmovertrukne tabletter 15 filmovertrukne tabletter 20 filmovertrukne tabletter 21 filmovertrukne tabletter 30 filmovertrukne tabletter 50 filmovertrukne tabletter 100 filmovertrukne tabletter
1 film-coated tablet 2 film-coated tablets 3 film-coated tablets 5 film-coated tablets 7 film-coated tablets 10 film-coated tablets 14 film-coated tablets 15 film-coated tablets 20 film-coated tablets 21 film-coated tablets 30 film-coated tablets 50 film-coated tablets 100 film-coated tablets
Brug af anden medicin sammen med Neoclarityn Der er ingen kendte interaktioner mellem Neoclarityn og andre lægemidler.
There are no known interactions of Neoclarityn with other medicines.
Det frarådes, at du tager Neoclarityn, hvis du er gravid, eller hvis du ammer dit spædbarn.
Taking Neoclarityn is not recommended if you are pregnant or nursing a baby.
Virkningen af Neoclarityn-tabletter er ikke blevet tydeligt vist i studier med unge patienter mellem 12 og 17 år.
The efficacy of Neoclarityn tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.
I kliniske studier med Neoclarityn er følgende bivirkninger blevet rapporteret som:
In clinical studies with Neoclarityn, the following side effects were reported as:
Virkningen af Neoclarityn syrup er ikke undersøgt i pædiatriske studier med børn under 12 år.
Efficacy of Neoclarityn syrup has not been investigated in paediatric trials in children less than 12 years of age.
I et separat studie havde grapefrugtjuice ingen indflydelse på omsætningen af desloratadin.
In a separate study, grapefruit juice had no effect on the disposition of desloratadine.
Hvis du har glemt at tage Neoclarityn smeltetabletter Hvis du glemmer at tage din medicin til tiden, så tag den snarest muligt og vend derefter tilbage til din sædvanlige medicineringsplan.
If you forget to take Neoclarityn orodispersible tablet If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule.
Bivirkninger set med Neoclarityn
Adverse reactions seen with Neoclarityn
Ved den anbefalede dosis blev Neoclarityn 5 mg smeltetablet fundet værende bioækvivalent med den konventionelle Neoclarityn 5 mg tabletformulering af desloratadin.
At the recommended dose, Neoclarityn 5 mg orodispersible tablet was found to be bioequivalent to the Neoclarityn 5 mg conventional tablet formulation of desloratadine.